IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Paradiem LLC

Paradiem LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 41.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,486 shares of the medical research company’s stock after selling 7,981 shares during the period. Paradiem LLC’s holdings in IQVIA were worth $2,658,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at about $13,759,000. Schwartz Investment Counsel Inc. raised its position in shares of IQVIA by 4.1% in the fourth quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock valued at $41,345,000 after buying an additional 7,050 shares during the last quarter. Dfpg Investments LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at about $1,106,000. Sei Investments Co. raised its position in shares of IQVIA by 20.2% in the third quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock valued at $18,641,000 after buying an additional 15,913 shares during the last quarter. Finally, Duality Advisers LP acquired a new stake in shares of IQVIA in the third quarter valued at about $491,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Up 0.4 %

NYSE:IQV traded up $0.90 during mid-day trading on Friday, hitting $234.88. The stock had a trading volume of 697,640 shares, compared to its average volume of 761,918. The stock has a 50-day simple moving average of $245.28 and a two-hundred day simple moving average of $223.17. The company has a market capitalization of $42.63 billion, a PE ratio of 32.22, a PEG ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter last year, the company earned $2.54 earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. UBS Group increased their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. SVB Leerink assumed coverage on shares of IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 target price for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Barclays raised their price objective on shares of IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Finally, Truist Financial raised their price objective on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.